SCI Epidemiology and Complications

February 19, 2026 updated by: Nurten NAS KIRDAR, Bandırma Onyedi Eylül University

Epidemiological Evaluation and Complications of Spinal Cord Injury Patients Admitted to Our Clinic: A Retrospective Study

The aim of this study was to epidemiologically evaluate patients diagnosed with spinal cord injury who were admitted to our clinic over the last five years and, unlike similar studies, to investigate the presence of complications in these patients. The investigators hope that this study will contribute to the literature by raising awareness of spinal cord injury epidemiology and potential complications.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

This study was designed as a retrospective descriptive study. Patients who were admitted to the Physical Medicine and Rehabilitation outpatient clinic of Bandırma Training and Research Hospital with a diagnosis of paraplegia or tetraplegia between December 1, 2020, and December 1, 2025, were included in the study. These diagnoses were screened using the following ICD-10 codes: G82 (paraplegia and tetraplegia), G82.0 (flaccid paraplegia), G82.1 (spastic paraplegia), G82.2 (paraparesis and paraplegia, unspecified), G82.3 (flaccid tetraplegia), G82.4 (spastic tetraplegia), and G82.5 (tetraplegia, unspecified).

Data regarding patients' age, sex, etiology of spinal cord injury, level of injury, and the presence of complications were recorded. In cases where complications were present, the time from injury to the development of complications was recorded in months.

Since the most common causes of spinal cord injury differ across age groups, age categories were defined as ≤29 years, 30-44 years, 45-59 years, 60-74 years, and ≥75 years. Etiological classification was based on the most common causes reported in the literature, including traffic accidents, falls from height, sports-related injuries, post-disc herniation or surgery, non-traumatic/inflammatory causes, and other causes.

As the level of injury affects both clinical presentation and the development of complications, injury levels were categorized as cervical (C1-C8), thoracic (T1-T12), and lumbosacral (L1-S5). Evaluation parameters and grouping methods were determined based on similar studies reported in the literature.

Study Type

Observational

Enrollment (Estimated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Turkey (Türkiye)
    • Bandırma
      • Balıkesir, Bandırma, Turkey (Türkiye), 10200
        • Bandırma Onyedi Eylul University Faculty of Medicine
        • Contact:
        • Principal Investigator:
          • Nurten Nas Kırdar, Assistant Professor

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Patients who presented to our hospital's Physical Medicine and Rehabilitation outpatient clinic with diagnoses of paraplegia and tetraplegia between December 1, 2020, and December 1, 2025.

Description

Inclusion Criteria:

  • clinical diagnosis of paraplegia
  • clinical diagnosis of tetraplegia

Exclusion Criteria:

  • traumatic brain injury
  • brain tumor
  • cranial lesions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients who presented to our clinic with SCI between December 1, 2020, and December 1, 2025
Patients who presented to our hospital's Physical Medicine and Rehabilitation outpatient clinic with diagnoses of paraplegia and tetraplegia between December 1, 2020, and December 1, 2025.
Other: Retrospective data analysis
Patient data regarding age, gender, etiology of spinal cord injury, level of injury, and whether complications develop will be recorded.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Average age and gender of patients followed up in our clinic due to spinal cord injury
Time Frame: 1 month
-Average age and gender of patients followed up in our clinic due to spinal cord injury
1 month
Etiology of injury in patients followed up in our clinic due to spinal cord injury
Time Frame: 1 month

Etiology of injury in patients followed up in our clinic due to spinal cord injury

  1. Traffic accident
  2. Fall from a height
  3. Sports injuries
  4. Disc herniation/post-surgery
  5. Non-traumatic causes/Inflammatory causes
  6. Other causes
1 month
Stage of injury in patients followed up in our clinic due to spinal cord injury
Time Frame: 1 month

-Stage of injury in patients followed up in our clinic due to spinal cord injury

  1. C1-C8
  2. T1-T12
  3. L1-S5
1 month
Whether or not complications developed in patients followed up in our clinic due to spinal cord injury
Time Frame: 1 month

-Whether or not complications developed in patients followed up in our clinic due to spinal cord injury

These complications include: Pressure ulcer, Urinary tract infection, Deep vein thrombosis, Joint contracture, Osteoporosis/fracture, Spasticity, Autonomic dysreflexia, Psychological problems, Sexual problems, Charcot joint, Urethral stricture, Post-traumatic syringomyelia, Heterotopic ossification, Other systemic problems (respiratory problems, cardiac problems, gastrointestinal problems, metabolic and endocrine problems).
1 month

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the time when the complication developed
Time Frame: 1 month
- In patients followed up in our clinic due to spinal cord injury who developed complications, the time when the complication developed.
1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Bandırma Onyedi Eylül University

Investigators

  • Principal Investigator: Nurten Nas Kırdar, Assistant Professor, Bandırma Onyedi Eylül University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

March 1, 2026

Primary Completion (Estimated)

March 31, 2026

Study Completion (Estimated)

April 10, 2026

Study Registration Dates

First Submitted

February 5, 2026

First Submitted That Met QC Criteria

February 19, 2026

First Posted (Actual)

February 20, 2026

Study Record Updates

Last Update Posted (Actual)

February 20, 2026

Last Update Submitted That Met QC Criteria

February 19, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • E-67961857-050.04-2500085688

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

If the results of our study are deemed suitable for publication in an appropriate journal after peer review, they will be accessible to all researchers once published.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe